Time New York: Wed 17 Oct 20:31 pm  |  Save 15% on H&R Block Online


Can Continental Resources (CLR) Run Higher on Strong Earnings Estimate Revisions?


Continental Resources, Inc. CLR is a crude-oil concentrated, independent oil and natural gas exploration and production company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on CLR’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Continental Resources could be a solid choice for investors.

Current Quarter Estimates for CLR

In the past 30 days, eight estimates have gone higher for Continental Resources while one has gone lower in the same time period. The trend has been pretty favorable too, with estimates increasing from 14 cents a share 30 days ago, to 20 cents today, a move of 42.9%.

Current Year Estimates for CLR

Meanwhile, Continental Resources current year figures are also looking quite promising, with 11 estimates moving higher in the past month, compared to two lower. The consensus estimate trend has also seen a boost for this time frame, increasing from 20 cents per share 30 days ago to 29 cents per share today, an increase of 45%.

Continental Resources, Inc. Price and Consensus

Continental Resources, Inc. Price and Consensus | Continental Resources, Inc. Quote

Bottom Line

The stock has also started to move higher lately, adding 10.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So, investors may want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

To read this article on Zacks.com click here.

Zacks Investment Research
<-- You can share this post with your network,
or give us your opinion and leave a comment.
Be sure to check our RSS feeds for updates.